Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease




In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma kinase (ALK) gene. The drug also has shown dramatic responses in patients whose lung cancers harbored a different molecular abnormality, namely ROS1 gene rearrangements.

Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/2...

Sábado, 31 de Mayo 2014
Jueves, 1 de Enero 1970
1

1 1
Otros artículos de esta sección